Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

February 16, 2011

In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes

Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it received regulatory approval for the additional purpose of use with myelodysplastic syndrome, for its WT1 mRNA Assay Kit "Otsuka," an in-vitro diagnostic kit, in Japan on February 14, 2011. WT1 mRNA Assay Kit "Otsuka" is already approved as a MRD monitoring marker for acute myeloid leukemia in Japan.

Latest Pharmaceutical Business related News Releases

17 APR 2023

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

30 JAN 2023

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan

10 JAN 2023

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Most Recent Releases

Otsuka Pharmaceutical Co., Ltd.

In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes

Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan

Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology

Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti^® (brexpiprazole) in Japan